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Introduction
The South East Asia Infectious Disease
ClinicalResearchNetwork(SEAICRN)isa
collaborative partnership of hospitals and
institutions in Thailand, Vietnam, Indone-
sia, and Singapore. The network strives to
advance scientific knowledge and clinical
and laboratory management of infectious
disease in general, and influenza in partic-
ular, through integrated, collaborative clin-
ical research in the South East Asia region
(see http://www.seaicrn.org/) [1]. The
establishment of this network helps fulfill
the declaration of the World Health
Assembly in 2005 that urged its member
states to ‘‘strengthen national laboratory
capacity for human and zoonotic influen-
za,’’ and ‘‘to support an international
research agenda to reduce the spread and
impact of pandemic influenza viruses’’
[2,3]. In addition it also supports the
recently revised International Health Reg-
ulations (IHR 2005),which came intoeffect
in 2007, by increasing surveillance and
response capacity in strategic hospitals,
national institutes, and referral laboratories
and by promoting international collabora-
tion and sharing of data [3].
SEAICRN’s first intervention study was
a multicenter randomized clinical trial in
four Asian countries that compared the
efficacy of high dose (150 mg bid) versus
standard dose (75 mg bid) oseltamivir for
severe influenza (Table 1). Subsequently
the SEAICRN initiative developed a series
of research protocols related to influenza
and other infectious diseases being imple-
mented in participating institutions. To
make these studies possible, and to comply
with international laboratory and clinical
trial standards, the SEAICRN recently
chose to enhance the capacity and quality
of both the research and clinical laborato-
ries at all participating hospitals and
institutions in the region.
The key objective of the laboratory
strengthening program was to enhance
laboratory facilities; ensure availability of
necessary equipment; build human re-
source capacity by teaching, training,
and mentoring; and ensure quality labo-
ratory management and testing to comply
with good clinical laboratory practice
(GCLP) and other international standards
such as the ISO 15189 [4,5]. Here we
present the experiences of the SEAICRN
in setting up and conducting the labora-
tory capacity building program and dis-
cuss how this benefitted the institutions,
the research studies, and the region. The
US National Institutes of Health’s (NIH)
National Institute for Allergy and Infec-
tious Disease (NIAID) and Wellcome
Trust funding support for this program
has been described previously [1].
Creating Laboratory Capacity
Given that SEAICRN laboratories had
different levels of organization and exper-
tise, it was considered important to create
reference laboratories for different aspects
of the research activities in each country
(Figure 1). Due to the initial focus on
influenzatherapeutics,aSEAICRNclinical
pharmacology laboratory was established
at the Department of Tropical Medicine,
Mahidol University, Bangkok, Thailand.
To enroll patients into the first clinical
trial, participating sites needed to be able
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transcriptase polymerase chain reaction
(RT-PCR) reliably, rapidly, and accurate-
ly. To be able to screen patients by RT-
PCR, several laboratories were renovated
to house, for the first time, a molecular
diagnostic laboratory (MDL), with all the
required infrastructure, equipment, re-
agents, and consumables. Physical separa-
tion of spaces for reagent preparation,
nucleic acid extraction, and amplification
was ensured in all laboratories to prevent
PCR contamination. Also, a new biosafety
level 3 laboratory facility was established
at the Hospital for Tropical Diseases, Ho
Chi Minh City, Viet Nam for isolation of
H5N1 viruses and emerging (pandemic)
influenza viruses. Additionally, in Viet
Nam, (pyro)sequencing capacity was es-
tablished to characterize viruses and detect
mutations in the influenza virus genome
that confer antiviral drug resistance.
Site staff from Bangkok, Jakarta, Ban-
dung, Hanoi, and Ho Chi Minh City were
Summary Points
N Enhancing laboratory capacity is essential for generating reliable and accurate
data from clinical research, especially in resource-constrained settings.
N Local well-trained laboratory experts and scientists are important to research,
and must participate actively in scientific activities and continuing education
programs.
N Improving laboratory capacity is more than supplying new equipment and
reagents; it also includes a long-term commitment to staff training, quality
control, and biosafety.
N Improved laboratory capacity optimizes responses to an epidemic or an
outbreak of a novel virulent pathogens, and can support international agendas
to reduce the impact of pandemic influenza viruses.
Table 1. List of approved protocols that will be or are being executed by SEAICRN.
Study
Number
Clinical Trial
Registry Number Title Status
SEA001 NCT00298233 High-dose versus standard-dose oseltamivir for the treatment of severe influenza
and avian influenza. A phase ii double-blind, randomized clinical trial
Study finished.
Awaiting analysis
SEA002 NCT00439530 Pharmacology Study of oseltamivir and probenecid in healthy Asian subjects Published
SEA003 NCT00921726 Phase 1, open-label study to evaluate potential pharmacokinetic interactions between
orally-administered oseltamivir and intravenous zanamivir in healthy Thai adult subjects
Study finished.
Awaiting analysis
SEA004 NCT00980109 Long term influenza prophylaxis with inhaled zanamivir or oral oseltamivir Ongoing
SEA005 Pending An open label study to evaluate the safety, tolerability and efficacy of intravenous
zanamivir administered twice daily for 5 days in hospitalized subjects with
confirmed H5N1 influenza infection.
Will start 2010
SEA006 — Clinical database of patients with H5N1 infection Ongoing
SEA007 — Host genetic susceptibility to human influenza A/H5N1 Ongoing
SEA008 — Cardiorespiratory function and radiological changes in lung structure in Indonesian
patients who survive highly pathogenic influenza A/H5N1—A 3 year prospective study
Ongoing
SEA013 Pending Open-label study to evaluate potential pharmacokinetic interactions between orally
administered oseltamivir and intravenous peramivir in healthy Thai adult subjects
Tentatively scheduled
after January 2010
SEA019 — Non-Influenza etiologies of acute respiratory illness in Southeast Asia Ongoing
SEA022 Pending Oseltamivir treatment in severe, virologically confirmed influenza A or B in hospitalized
children less than one year of age in Hanoi, Ho Chi Minh City and Bangkok
Expected to start
in 2010
SEA023 — The viral etiology of hospitalized children less than one year of age with an acute,
community acquired, lower respiratory tract infection in Hanoi and Bangkok
Expected to start
in 2010
SEA024 Pending Efficacy of primaquine against relapse by Plasmodium vivax in Indonesia Expected to start
in 2010
SEA025 — A survey of acute febrile illnesses in adults and children at the Cipto Mangunkusumo
hospital, Jakarta, Indonesia
Expected to start
in 2010
SEA026 — Characterization of the human carboxylesterase 1 (CES 1) mutation(s) which may be
responsible for markedly reduced conversation of oseltamivir phosphate to oseltamivir
carboxylate, and determination of frequency in SE Asian population
Ongoing
SEA027 — Acute post-infectious measles encephalitis Finished. Awaiting
analysis
SEA028 — Hand, foot, and mouth disease Protocol in development
SEA029 Pending A randomized, open-label, comparative trial of the efficacy of itraconazole versus
Amphotericin B in the treatment of penicilliosis in HIV-infected persons
Will start beginning
of 2010
SEA030 Pending An open label study to evaluate the safety, tolerability and efficacy of intravenous
zanamivir administered twice daily for 5 days in hospitalized subjects with confirmed
seasonal influenza infection
Pending
SEA032 NCT00985582 Oseltamivir treatment in adults and children with mild or moderate influenza
H1N12009 infection—a clinical, virological and pharmacokinetic study
Ongoing
Study SEA002 is finished and already published [13].
doi:10.1371/journal.pmed.1000231.t001
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diagnostics and molecular diagnostics in
general, including principles of unidirec-
tional workflow and prevention of carry-
over contamination. These trainings were
performed on an ongoing basis at the
reference laboratory in Ho Chi Minh City,
followed by on-site training. To ensure
quality, each MDL laboratory was en-
rolled in at least two different external
quality assurance programs for molecular
influenza diagnostics. Furthermore, profi-
ciency testing for diagnosing influenza by
RT-PCR was performed before sites were
allowed to start screening patients for the
studies.
Each hospital is encouraged to use the
MDL for purposes other than SEAICRN-
related research activities, such as HIV,
hepatitis, dengue, meningitis, and enceph-
alitis testing by molecular techniques. The
philosophy is that it is important and
highly beneficial to increase expertise in
detecting infectious agents by molecular
diagnostics and so stimulate the imple-
mentation of other relevant molecular
diagnostic tests. For example, after imple-
mentation of a Streptococcus suis–specific
molecular test in the MDL of the National
Hospital of Tropical Diseases, Vietnam, it
was found that S. suis is a common cause of
bacterial meningitis in adults in Hanoi [6].
In preparation for the start of the
clinical trials, dedicated laboratory trial
staff members were appointed to become
staff of the national institutions. They
received training on processing, labeling,
testing, storing, shipping, and document-
ing data from trial specimens according to
protocol requirements. A centralized spec-
imen labeling and database system was set
up to track and trace all stored specimens
for the SEAICRN studies. Currently the
SEAICRN uses Freezerworks software
(Dataworks Development; http://www.
freezerworks.com/) to track study speci-
mens and aliquots. Sites received deep
freezers for adequate specimen storage
and power back-up systems were installed
where needed to ensure an uninterrupted
power supply. Table 2 summarizes the
required laboratory capacity and what was
done to achieve this.
The laboratory capacity program of the
SEAICRN enabled us to rapidly respond to
changes in influenza epidemiology, such as
thespreadofnaturallyoccurringoseltamivir
resistance in seasonal H1N1 viruses and the
recent emergence of the novel influenza A
(H1N1) strain (pH1N1) in April 2009. In
response to the increasing rates of oseltami-
vir resistance in seasonal H1N1 viruses,
before the emergence of pH1N1, the
laboratory committee decided to test Asian
isolates and respiratory specimens from
influenza patients in our studies [7,8]. This
step generatedvaluable resistancedata from
theregion, which wereinstantly shared with
the national and international medical and
scientific community. In April 2009, when
confronted with a pandemic threat of this
novel influenza virus, we prepared collabo-
rating laboratories by providing them with
sequence information of this strain and
primers and probes to enablethemtodetect
it by RT-PCR. Furthermore, we were able
to describe the first worldwide transmission
of oseltamivir resistant pH1N1 in a com-
munity cluster [9].
Laboratory Quality
Enhancement Program
In partnership with Family Health
International (FHI), the SEAICRN initi-
ated a clinical laboratory quality improve-
ment program in the region. This includ-
ed: (i) baseline assessment of each hospital
clinical laboratory against international
standards, ( ii) inventory, maintenance,
and calibration of instruments, (iii) enroll-
ment in external quality assurance pro-
gram, (iv) assessment of training needs, (v)
review of normal reference values used in
the laboratory, and (vi) accreditation status
of the laboratories by local and interna-
tional accreditation bodies. The baseline
assessments evaluated the overall quality
of the clinical laboratory and helped to
develop short- and long-term recommen-
dations for improvement. Based on the
assessment and recommendations, subse-
quent follow-up visits and technical sup-
port were provided to each hospital to
implement those recommendations.
Laboratory management staff in each
hospital were trained and encouraged to
implement a quality management system.
This included development and imple-
mentation of quality and technical manu-
als, standard operating procedures (SOPs),
and a document control system. To help
to improve laboratory quality it was
necessary to appoint a senior staff member
as a Quality Officer to oversee all aspects
of laboratory quality and the quality
enhancement program. Furthermore,
each laboratory was supported with nec-
essary instruments, and staff were encour-
aged to establish and monitor an equip-
ment maintenance and calibration
program. All staff from each laboratory
were trained on standards developed by
the technical committee of the Interna-
tional Organisation for Standardisation
(ISO15189:2003 and ISO15190:2003,
http://www.iso.org/) [10].
During the clinical trials it was noticed
that occasionally reported biochemistry
results were implausible. In response, a
continuous improvement system was im-
plemented to ensure that laboratory test
results are reviewed by a qualified person
to identify performance issues. In addition,
advice was given on proper use of internal
controls, how to monitor and investigate
the possible cause(s) of controls not
meeting acceptance criteria, and correc-
Figure 1. South East Asia Infectious Disease Clinical Research Network sites and
laboratories.
doi:10.1371/journal.pmed.1000231.g001
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performance issues are identified. Labora-
tories were encouraged to complement the
capacity of each other by establishing a
specimen testing referral linkage among
them.
The overall activities of the SEAICRN
created opportunities for laboratory staff
to exchange experiences with senior labo-
ratory personnel. In addition, a laboratory
networking system and a platform for
sharing experiences among laboratories
was established through the SEAICRN
annual meetings and regular teleconfer-
ences. Also, as part of the development of
new clinical protocols there has been a
strong interaction between laboratory
experts, clinicians, and trial support staff.
Having such systems in place have proved
crucial to the ability of these clinical
laboratories to respond quickly to the
spread of oseltamivir-resistant influenza
A/H1N1 and pH1N1. With the infra-
structure in place it proved possible to
respond immediately to the pH1N1 pan-
demic. It was also possible to implement a
clinical research protocol in Viet Nam and
start to make the data available in less than
a month from the appearance of the first
cases.
The ultimate goal of the program was to
improve the quality of laboratory services,
achieve compliance with GCLP standards,
gain ISO 15189 accreditation, and facili-
tate better clinical care and collaborative
research. Setting such goals makes the
process more real and motivates laborato-
ry staff to participate. Several laboratories
in Thailand had already started working
toward accreditation independently of the
SEAICRN, and these efforts helped facil-
itate the SEAICRN program at those sites.
Two laboratories in Thailand received
‘‘The Association of Medical Technolo-
gists of Thailand’’ accreditation, and one
laboratory in Thailand and two in Viet-
nam have gained ISO15189 accreditation.
In addition, another laboratory in Thai-
land and one in Indonesia are nearly ready
for accreditation inspection.
Discussion
Although GCLP is the standard in
developed countries, it can pose a dispro-
portionate burden and significant chal-
lenge in resource-constrained settings
(see Box 1). However, it was clear that
laboratory staff were motivated to im-
prove the quality of their testing and
services when working toward a concrete
endpoint, such as ISO15189 accredita-
tion. A GCLP standard for resource-
constrained settings that is simpler and
less demanding on resources is urgently
needed [5,11].
It is important that laboratory enhance-
ment programs focus not only on the
particular disease of research interest, so that
the investments can also benefit other diseases
and routine patient care [12]. Setting up the
SEAICRN has served as a catalyst for
laboratories to implement molecular diag-
nostic techniques as part of routine care, not
only for influenza but for a range of other
pathogens beyond direct research needs. The
SEAICRN has provided tools, training
(including short courses, Masters, and PhD
programs), and protocols to facilitate these
processes. Currently, six scientists from Asia
are enlisted in a PhD program, nine in a
Masters program, three in a Bachelor’s
program, and 295 in a short-term fellowship.
A total of 2,146 individuals have participated
in operational training activities organized or
made possible by the SEAICRN.
The sharing of data has been a
contentious issue over the last few years.
The SEAICRN has a policy that all the
protocols, case record forms, SOPs, and
manuals of operations for all studies and
for all processes are made available via the
internet at the start of all studies (http://
www.seaicrn.org/). During the pH1N1
pandemic, a number of non-Asian coun-
tries used these protocols, adapted them to
their own local circumstances, including
translation, and implemented them.
SEAICRN is also committed to sharing
Table 2. Activities by SEAICRN to achieve required laboratory capacity for their research projects.
Context Capacity/Expertise Required Activity
Infrastructure Uninterrupted power supply UPS systems installed
Sufficient freezer capacity for study specimen storage Provided freezers
MDL Create MDL where needed and train staff.
Quality and safety External quality assurance (EQA) of laboratory tests Provided EQA (Thai program)
Equipment maintenance Ensured maintenance
Temperature logs Set up temperature logging system
Laboratory safety Provide safety cabinets and biosafety training
Laboratory test normal ranges Provided guidance in establishing normal ranges
Laboratory result documentation Improved where needed
Laboratory accreditation Laboratory quality enhancement program implemented
Specimen/aliquot tracking and tracing Implemented a central labeling system and database
Shipment of infectious substances Training in shipping biological substances
Specific laboratory
testing
Influenza molecular diagnostic test Set up CDC assay for influenza real-time RT-PCR
Neuraminidase inhibitor resistance testing Set up neuraminidase inhibition assay and molecular
based test (sequencing)
Oseltamivir plasma concentrations Set up pharmacokinetic laboratory
Laboratory tests for adverse events In case unavailable, set up referral system.
Blood culture Provided blood culture system
Other Listen for local needs and challenges and provide
technical assistance when able to do so.
Provided technical assistance and support as part of
the program
doi:10.1371/journal.pmed.1000231.t002
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and international authorities, in line with
the IHR 2005. However, it is also crucial
for scientists and clinicians within coun-
tries and within regions to know each
other, to have built sustainable relation-
ships and networks in a manner that
encourages and facilitates the exchange
of experience and information within the
regional clinical and scientific community.
Clearly, the success and sustainability of
a research network depends on funding.
The current support for the SEAICRN
ends in September 2010, but investigators
across the region are committed to
continuing the network, and funding has
been secured to ensure its sustainability
beyond that date. There is a clear
commitment to extend the network be-
yond the current centers in the four
countries in Asia. Other centers have
expressed an interest in joining or sup-
porting such an expansion. The long-term
aim is to build a sustainable clinical
research network with its center of gravity
firmly based in Asia.
Having a wider perspective has proven
invaluable. Furthermore, the SEAICRN
was able to respond immediately in
assessing oseltamivir resistance in seasonal
influenza A/H1N1 in 2008, providing
vital information to the scientific and
medical community. We believe this
program has improved the clinical and
research laboratory capacity and quality in
the region. Besides enhancing research in
Asia, the investments have also helped
improve health care for all patients served
at the participating hospitals. Our pro-
gram addresses the issues raised by the
World Health Assembly in 2005 and in
the revised International Health Regula-
tions, as it supports the region to be more
prepared to deal with potential pandemic
influenza viruses and other endemic and
emerging infectious diseases, as we have
recently experienced, and promotes inter-
national collaboration and sharing of data.
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Box 1. Key Challenges
1. Improving laboratory capacity requires investment in both time and money. It is
essential that long term goals are set, as opposed to short term fixes, and that
the finances are made available to enable and sustain continuous quality
improvements.
2. Laboratories will be at different stages of implementing an international-level
quality system. A capacity building program should be tailored to each
laboratory taking cultural, technical, and financial differences into account.
Working towards accreditation is a concrete and achievable goal and helps to
motivate staff.
3. International accreditation (e.g. ISO15189:2003) may not always be desirable
and sustainable in resource-constrained settings as the ongoing costs may be
too high. It is worthwhile to explore alternate accreditation models in such
settings, which can be used as a stepwise approach to full international
accreditation.
4. Improving laboratory quality systems requires financial commitment and
support from the hospital director and a time commitment from laboratory
leadership and staff. All need to be convinced that improvement is essential for
delivering good quality health care. Research activities should not be solely
responsible for funding the running costs of quality systems as this would not
be sustainable with the systems potentially ending when the research funding
stops.
5. Not all countries have accreditation authorities that can accredit laboratories as
qualified people are not available. The capacity for national or regional
accreditation should be improved in the near future.
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